Author: Sarah Collins

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

UnitedHealth Group (UNH) released its Q3 2018 earnings today. UNH reported sales of $56.6 billion, up ~12.4% on a year-over-year basis.

Johnson & Johnson (JNJ) reported its third-quarter earnings before the market opened today. It reported sales of $20.3 billion, up 3.6% YoY.

Edwards Lifesciences is set to release its third-quarter earnings results after the market closes on October 23. Let's see what to expect.

Teva is gradually recovering from the lows it witnessed in late 2017 due to generics competition, pricing pressure, and declining Copaxone sales.

Most healthcare stocks fell yesterday amid the broader market sell-off. Biotech players seem to have been hit the worst.

Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.

Of the 24 analysts covering UNH stock, ten have recommended a “strong buy," and 13 have recommended a "buy."

Today, Morgan Stanley downgraded Mylan (MYL) from "overweight" to "equal weight." The firm also cut its target price for MYL stock from $46 to $36.

Johnson & Johnson (JNJ) plans to announce its Q3 earnings on October 16. On October 9, 50% of analysts covering JNJ rated it as a “buy.”

On October 5, Johnson & Johnson (JNJ) stock opened at $137.43, a decline of ~0.51% compared to its closing price of $139.35 on October 4.